Ali Faraz's Form 4 filing
Tenaya Therapeutics, Inc. (TNYA) · filed Feb 17, 2026
- Accession no.
- 0001193125-26-055442
- Filed
- Feb 17, 2026
- Trade date
- Feb 17, 2026
- Filing delay
- Same day
- Rule 10b5-1 plan
- Not checked
This filing lists 3 non-derivative transactions. Open-market sales total $9.51K. It was filed on the trade date.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Ali FarazCIK 0001667937 | Director, Officer (Chief Executive Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 17, 2026 | Common Stock | SSaleDisposed | −5,851 | $0.64F2 | −$3,744.64 | 452,415 | Direct | |
| Feb 17, 2026 | Common Stock | SSaleDisposed | −3,979 | $0.64F2 | −$2,546.56 | 448,436 | Direct | |
| Feb 17, 2026 | Common Stock | SSaleDisposed | −5,032 | $0.64F2 | −$3,220.48 | 443,404 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $0.6075 to $0.671. Reporting Person undertakes to provide Tenaya Therapeutics, Inc., any security holder of Tenaya Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
Referenced by the price of 3 transactions in Table I.